Abbott Laboratories ABT shares are trading at a discount to the Zacks Medical Products industry. Its trailing 12-month price-to-book value ... s average of 8.77. The stock also remains ...

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS ...

The company reported revenue of $10.97 billion and earnings of $1.34 on a per-share and adjusted basis, compared to the consensus estimates of $11.01 billion and ...

Abbott's Q4 sales grow 7.2%, missing estimates, but analysts remain upbeat with strong 2025 projections driven by Diabetes Care and Medical Devices.

ABT stock is not so cheap as its Value Score of C suggests a stretched valuation at this moment. In terms of the forward 12-month Price/Earnings ratio, Abbott’s shares are trading at 21.95X ...

Abbott Laboratories ABT shares are trading at a discount to the Zacks Medical Products industry. Its trailing 12-month price-to-book value of 4.91X is significantly lower than the industry average of ...